ProCE Banner Activity

CME

Management of Mild to Moderate COVID-19 in People Who Are Immunocompromised

Video

In this roundtable, experts discuss how to manage mild to moderate COVID-19 in patients who are immunocompromised based on the latest data and guideline recommendations. 

European Learners: 0.50 hours EBAC® effective education time

Released: January 07, 2025

Expiration: January 06, 2026

Share

Faculty

Michele Bartoletti

Michele Bartoletti, MD, PhD

Associate Professor of Infectious Diseases
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele (MI), Italy
Head of Infectious Diseases Unit
IRCCS Humanitas Research Hospital
Rozzano (MI), Italy

Cristina Mussini

Cristina Mussini, MD

Full Professor of Infectious Diseases
Division of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy

Sara Patient

Sara Patient

Patient

Martin Witzenrath

Martin Witzenrath, MD, FERS

Medical Director
Charite Centrum 12
Internal Medicine & Dermatology
Professor and Chair for Respiratory Medicine and Critical Care
Department of Infectious Disease, Respiratory Medicine and Critical Care
Charite Campus Mitte/Campus Virchow Klinikum/Campus Benjamin Franklin
Charite – University of Berlin
Berlin, Germany

Provided by

Provided by Clinical Care Options, LLC, in partnership with Practicing Clinicians Exchange, ProCE, and the American Academy of Emergency Medicine (AAEM)

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

American Academy of Emergency Medicine (AAEM)

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

ProCE

ProCE Banner

Target Audience

This activity is intended for European healthcare professionals involved in the care of hospitalized patients with COVID-19.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with COVID.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Identify hospitalized patients with COVID-19 who are at risk for severe outcomes to guide therapeutic plans

  • Integrate clinical practice guideline recommendations into inpatient COVID-19 management strategies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Michele Bartoletti, MD, PhD

Associate Professor of Infectious Diseases
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele (MI), Italy
Head of Infectious Diseases Unit
IRCCS Humanitas Research Hospital
Rozzano (MI), Italy

Michele Bartoletti, MD, PhD, has no relevant financial relationships to disclose.

Cristina Mussini, MD

Full Professor of Infectious Diseases
Division of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD: consultant/advisor/speaker: Gilead, Johnson & Johnson, Merck Sharp & Dohme, ViiV.

Sara Patient

Patient

Sara has no relevant financial relationships to disclose. 

Martin Witzenrath, MD, FERS

Medical Director
Charite Centrum 12
Internal Medicine & Dermatology
Professor and Chair for Respiratory Medicine and Critical Care
Department of Infectious Disease, Respiratory Medicine and Critical Care
Charite Campus Mitte/Campus Virchow Klinikum/Campus Benjamin Franklin
Charite – University of Berlin
Berlin, Germany

Martin Witzenrath, MD, FERS: researcher: Aptarion, Bayer, Biotest, Boehringer Ingelheim; consultant/advisor/speaker: AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Chiesi, Gilead, Hexal, Insmed, Novartis, Pantherna, Pfizer.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 07, 2025, through January 06, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

EBAC® Accreditation 

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.5 hours of effective education time. 

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively. 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™. 

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).